A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
A study for patients with myelofibrosis (bone marrow disorder) using study drug INCB050465
Sponsor: Incyte Corporation
Enrolling: Male and Female Patients
IRB Number: AAAR0403
U.S. Govt. ID: NCT02718300
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this research study is to determine the effects of INCB050465 in combination with ruxolitinib treatment on spleen size and/or symptoms and to learn about any of the side effects that might occur during or following dosing with this combination of molecules in patients diagnosed with myelofibrosis.
This study is closed
Mark Heaney, MD, PhD
Do You Qualify?
Have you been diagnosed with myelofibrosis? Yes No
Are you 18 years or older? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator